Skip to content
Open in App
BeOne Medicines logo

BeOne Medicines

web2

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatmen...

Symbol · 688235
Company profile

About

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

BEQALZI receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma

KEY STEP

On May 13, 2026, the FDA granted accelerated approval to BEQALZI, or sonrotoclax, for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor. Continued approval is contingent on confirmation of clinical benefit.

Roadmap reference

TEVIMBRA regimen receives FDA approval for first line HER2 positive gastroesophageal cancer

KEY STEP

On August 25, 2026, the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy for first line treatment of adults with HER2 positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.

Roadmap reference

BeOne expands Hopewell manufacturing with an additional $300 million investment

KEY STEP

On July 23, 2026, BeOne announced a $300 million expansion of its Hopewell, New Jersey manufacturing and research facility, bringing announced US manufacturing investment to more than $1 billion and adding small molecule manufacturing capacity.

Roadmap reference
People

Company team

XW

Xiaodong Wang

Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder

Company leadership profile.

DP

David P. Schenkein

Member of Scientific Advisory Board

Company leadership profile.

JV

John V. Oyler

Co-Founder, Executive Chairman & CEO

Company leadership profile.

AC

Anthony C. Hooper

Chairman of Commercial & Medical Affairs Advisory Committee and Ind. Non Executive Director

Company leadership profile.

MH

Margaret Han Dugan

Member of Scientific Advisory Committee & Independent Non-Exec. Director

Company leadership profile.

SS

Shalini Sharp

Independent Non-Executive Director

Company leadership profile.

NR

Neal Rosen

Member of Scientific Advisory Board

Company leadership profile.

CL

Charles L. Sawyers

Director

Company leadership profile.

AR

Alessandro Riva

Member of Scientific Advisory Committee & Director

Company leadership profile.

OB

Olivier Brandicourt

Independent Non-Executive Director & Commercial and Medical Affairs Advisory Committee

Company leadership profile.

EF

Elizabeth F. Mooney

Independent Non-Executive Director

Company leadership profile.

FJ

Felix James Baker

Non-Executive Director

Company leadership profile.

Expert coverage

1 expert evaluated BeOne Medicines.

Orbitrum research

Experts evaluating BeOne Medicines

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment